1. Home
  2. ENTA vs ONL Comparison

ENTA vs ONL Comparison

Compare ENTA & ONL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • ONL
  • Stock Information
  • Founded
  • ENTA 1995
  • ONL 2021
  • Country
  • ENTA United States
  • ONL United States
  • Employees
  • ENTA N/A
  • ONL N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • ONL Real Estate Investment Trusts
  • Sector
  • ENTA Health Care
  • ONL Real Estate
  • Exchange
  • ENTA Nasdaq
  • ONL Nasdaq
  • Market Cap
  • ENTA 112.4M
  • ONL 111.3M
  • IPO Year
  • ENTA 2013
  • ONL N/A
  • Fundamental
  • Price
  • ENTA $5.93
  • ONL $1.91
  • Analyst Decision
  • ENTA Buy
  • ONL Hold
  • Analyst Count
  • ENTA 4
  • ONL 1
  • Target Price
  • ENTA $17.25
  • ONL N/A
  • AVG Volume (30 Days)
  • ENTA 119.2K
  • ONL 636.5K
  • Earning Date
  • ENTA 05-12-2025
  • ONL 05-07-2025
  • Dividend Yield
  • ENTA N/A
  • ONL 4.19%
  • EPS Growth
  • ENTA N/A
  • ONL N/A
  • EPS
  • ENTA N/A
  • ONL N/A
  • Revenue
  • ENTA $64,462,999.00
  • ONL $154,796,000.00
  • Revenue This Year
  • ENTA N/A
  • ONL N/A
  • Revenue Next Year
  • ENTA N/A
  • ONL N/A
  • P/E Ratio
  • ENTA N/A
  • ONL N/A
  • Revenue Growth
  • ENTA N/A
  • ONL N/A
  • 52 Week Low
  • ENTA $4.09
  • ONL $1.46
  • 52 Week High
  • ENTA $17.24
  • ONL $4.39
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 55.39
  • ONL 50.82
  • Support Level
  • ENTA $5.55
  • ONL $1.63
  • Resistance Level
  • ENTA $6.23
  • ONL $2.02
  • Average True Range (ATR)
  • ENTA 0.33
  • ONL 0.11
  • MACD
  • ENTA 0.05
  • ONL 0.00
  • Stochastic Oscillator
  • ENTA 75.31
  • ONL 50.45

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About ONL Orion Office REIT Inc.

Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.

Share on Social Networks: